← Back to all trials
Recruiting
NCT07798505
A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers
Conditions: Healthy Adult Participants
Sex: All
Ages: 18 Years – 50 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 40
Sponsor: Hemab ApS
Location: Worldwide Clinical Trials San Antonio Texas
Summary
The purposes of this clinical study are
1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects.
2. To measure the amount of HMB-003 in the body after injection.
Eligibility Criteria
Inclusion Criteria:
* Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent.
* Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG.
Exclusion Criteria:
* Participant has a history of clinically significant hypersensitivity to any excipients of the study drug
* Participant is pregnant, breastfeeding, or \
Source: ClinicalTrials.gov (NCT07798505). StuddyBuddy aggregates publicly available trial information.
